Welcome to Men's Health Focus.

Please log in or register to view the content of this site.

This website provides free access to a range of men’s health related resources and has been developed by EPG Online with an educational grant and assistance from Bayer HealthCare Pharmaceuticals. The content of this site is intended for doctors and other healthcare professionals.

If you’re not a HCP please visit the Low Testosterone resource, or Erectile dysfunction resource for all the latest information.

As a disease topic Men's Health covers a broad set of issues affecting men of all ages. Some of the issues requiring greater focus and more thorough dissemination of information amongst the healthcare community, are those that have the potential to go undetected in the early stages. These include, hypogonadism and erectile dysfunction.

Early detection and more regular health checks of these diseases, not only improve prognosis and efficacy of treatment outcomes, but also quality of life.

Latest Updates

  • June 2014 - Testosterone and Prostate Cancer - a paradigm shift
    "Bye-bye Androgen Hypothesis, Welcome Saturation Model"

    Key Points

    • The "saturation model" explains the paradoxical observations that prostate tissue is extremely sensitive to changes in testosterone at low concentrations but becomes indifferent to changes at higher testosterone concentrations.
    • A threshold effect occurs in which increasing androgen concentrations reach a limit (the saturation point) beyond which there is no further ability to induce androgen-driven changes in prostate tissue growth.
    • A mechanism contributing to the saturation model is the finite ability of androgens to bind to the androgen receptor (AR). Maximal androgen-AR binding (i.e., saturation) occurs at fairly low androgen levels. It has been established in clinical practice that the saturation point appears to be around 8 nmol/L (230 ng/dL), subject to inter-individual variation.
    • The current ISA, ISSAM, EAU, EAA, ASA guidelines state:
      • There is no conclusive evidence that testosterone therapy increases the risk of prostate cancer or benign prostatic hyperplasia.
      • There is also no evidence that testosterone treatment will convert subclinical prostate cancer to clinically detectable prostate cancer.
    • Provocative new research evidence suggests that it is not high serum T that is problematic for PCa, but to the contrary that it is low serum T that is associated with worrisome prostate cancer features and outcomes.


If you are a healthcare professional and would like to gain free access to menshealthfocus.com you must register or login with your EPG Online username and password.

For your information, the menshealthfocus.com website concentrates on the understanding, management and treatment of erectile dysfunction and hypogonadism.  The website also provides extensive details on up-coming conferences as well as an extensive library of useful resource.

Terms of Use: